A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Terminated
Centocor, Inc.
Phase 2
2006-11-01
The purpose of this study is to assess the safety and efficacy of siltuximab administered in
combination with mitoxantrone and prednisone in participants with metastatic (spread of
cancer cells from one part of the body to another) hormone-refractory (not responding to
treatment) prostate cancer (abnormal tissue that grows and spreads in the body) (HRPC).
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Completed
Janssen Research & Development, LLC
Phase 2
2006-11-28
The purpose of Part 1 of the study is to determine the safety of the combination of
Siltuximab (CNTO 328) and bortezomib (Velcade). The purpose of Part 2 of the study is to
compare the length of progression free survival for those patients given CNTO 328 and
bortezomib to those patients given bortezomib alone.
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Completed
Centocor, Inc.
Phase 2
2006-10-01
The purpose of this study is to evaluate the safety and efficacy of siltuximab in
participants with relapsed (the return of a disease or the signs and symptoms of a disease
after a period of improvement.) or refractory (cancer that does not respond to treatment)
multiple myeloma (a type of cancer that begins in plasma cells [white blood cells that
produce antibodies]).
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Completed
Centocor, Inc.
Phase 1/Phase 2
2009-03-01
The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in
participants with solid malignant (cancerous) tumors (a mass in a specific area) and to
estimate the clinical benefit of siltuximab monotherapy in participants with ovarian cancer
and with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
